Cardiology

The EVOKE and EVOKE+ trials of oral semaglutide in 3,808 Alzheimer’s patients failed their primary endpoints, but stunning biomarker data, positive liraglutide brain volume results, and consistent real-world evidence from over a million patients suggest GLP-1 receptor agonists may still hold the key to neuroprotection. Here is what the science actually shows and where the field goes next.

A wave of FDA-cleared blood tests measuring phosphorylated tau 217 is transforming Alzheimer’s diagnosis from expensive brain scans and spinal taps into a routine blood draw at your doctor’s office. With accuracy exceeding 90 percent, the ability to predict symptom onset years in advance, and new treatments that work best when started early, the p-tau217 revolution is ushering in a new era of proactive brain health.

A 2025 network meta-analysis of 86 clinical trials and 7,276 participants reveals that resistance training significantly improves sleep quality, increases deep slow-wave sleep, reduces anxiety and inflammatory markers, and triggers a virtuous recovery cycle. Here is what the research says, and exactly how to build a training protocol that transforms your sleep starting this week.

For the first time in Parkinson’s disease history, three distinct therapeutic frontiers are advancing simultaneously through late-stage clinical trials. Stem cell grafts are surviving in human brains and restoring dopamine production. Gene-targeted drugs are addressing the root molecular causes in specific patient populations. And a new selective dopamine agonist may soon become the first novel oral Parkinson’s drug approved in over a decade. Here is where the science stands in spring 2026.